186 related articles for article (PubMed ID: 30991968)
1. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma.
Park Y; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yeon JE; Byun KS; Kim HS; Kim JH; Kim SU
BMC Cancer; 2019 Apr; 19(1):363. PubMed ID: 30991968
[TBL] [Abstract][Full Text] [Related]
2. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score.
Park Y; Kim SU; Kim BK; Park JY; Kim DY; Ahn SH; Park YE; Park JH; Lee YI; Yun HR; Han KH
Liver Int; 2016 Jan; 36(1):100-7. PubMed ID: 26013186
[TBL] [Abstract][Full Text] [Related]
3. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE).
Peisen F; Maurer M; Grosse U; Nikolaou K; Syha R; Ketelsen D; Artzner C; Bitzer M; Horger M; Grözinger G
Eur Radiol; 2020 Jul; 30(7):3782-3792. PubMed ID: 32125515
[TBL] [Abstract][Full Text] [Related]
4. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
5. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma.
Cappelli A; Cucchetti A; Cabibbo G; Mosconi C; Maida M; Attardo S; Pettinari I; Pinna AD; Golfieri R
Liver Int; 2016 May; 36(5):729-36. PubMed ID: 26604044
[TBL] [Abstract][Full Text] [Related]
6. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization.
Prajapati HJ; Kim HS
PLoS One; 2017; 12(2):e0170750. PubMed ID: 28170405
[TBL] [Abstract][Full Text] [Related]
7. Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study.
Pinato DJ; Arizumi T; Jang JW; Allara E; Suppiah PI; Smirne C; Tait P; Pai M; Grossi G; Kim YW; Pirisi M; Kudo M; Sharma R
Oncotarget; 2016 Jul; 7(28):44705-44718. PubMed ID: 27244889
[TBL] [Abstract][Full Text] [Related]
8. The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma.
Op den Winkel M; Nagel D; Op den Winkel P; Paprottka PM; Schmidt L; Bourhis H; Trojan J; Goeller M; Reiter FP; Stecher SS; De Toni EN; Gerbes AL; Kolligs FT
Digestion; 2019; 100(1):15-26. PubMed ID: 30282074
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
10. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
Li L; Gou CY; Li JY; Achakzai R; Li XH
Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
[TBL] [Abstract][Full Text] [Related]
11. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
12. Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients.
Jia K; Yin W; Gao Z; Shen W; Wang F; Xie S; Li M; Lv R
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):461-470. PubMed ID: 36827534
[TBL] [Abstract][Full Text] [Related]
13. Experience from a real-life cohort: outcome of 606 patients with hepatocellular carcinoma following transarterial chemoembolization.
Kirstein MM; Schweitzer N; Ay N; Boeck C; Lappas K; Hinrichs JB; Voigtländer T; Wacker F; Manns MP; Rodt T; Vogel A
Scand J Gastroenterol; 2017 Jan; 52(1):116-124. PubMed ID: 27598949
[TBL] [Abstract][Full Text] [Related]
14. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.
Chen ZX; Jian ZW; Wu XW; Wang JC; Peng JY; Lao XM
Cancer Med; 2019 Sep; 8(11):5097-5107. PubMed ID: 31313476
[TBL] [Abstract][Full Text] [Related]
15. HAP score as prognostic factor of hepatocellular carcinoma treated with transarterial chemoembolization in a Latin American center.
Liza Baca E; Díaz Ferrer J
Rev Gastroenterol Peru; 2018; 38(2):164-168. PubMed ID: 30118463
[TBL] [Abstract][Full Text] [Related]
16. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
Zhao Y; Li H; Bai W; Liu J; Lv W; Sahu S; Guan S; Qin X; Wang W; Ren W; Mu W; Guo W; Gu S; Ma Y; Yin Z; Guo W; Wang W; Wang Y; Duran R; Fan D; Zhang Z; Han G
Int J Cancer; 2016 Aug; 139(4):928-37. PubMed ID: 27038145
[TBL] [Abstract][Full Text] [Related]
17. Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma.
Pinato DJ; Pai M; Reccia I; Patel M; Giakoustidis A; Karamanakos G; Rushd A; Jamshaid S; Oldani A; Grossi G; Pirisi M; Tait P; Sharma R
BMC Cancer; 2018 Feb; 18(1):211. PubMed ID: 29463228
[TBL] [Abstract][Full Text] [Related]
18. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma.
Cohen MJ; Bloom AI; Barak O; Klimov A; Nesher T; Shouval D; Levi I; Shibolet O
World J Gastroenterol; 2013 Apr; 19(16):2521-8. PubMed ID: 23674854
[TBL] [Abstract][Full Text] [Related]
19. Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma.
Ha TY; Hwang S; Lee YJ; Kim KH; Ko GY; Ii Gwon D; Ahn CS; Moon DB; Song GW; Jung DH; Lee HC; Lim YS; Kim KM; Shim JH; Choi JH; Lee SG
World J Surg; 2016 May; 40(5):1200-10. PubMed ID: 26666422
[TBL] [Abstract][Full Text] [Related]
20. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W
Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
